Pharmacological Care in Patient with Focal Segmental Glomerulosclerosis Treated with Rituximab
10.3870/j.issn.1004-0781.2024.08.024
- VernacularTitle:利妥昔单抗治疗局灶节段性肾小球硬化患者的药学监护
- Author:
Caipeng XIE
1
;
Min TAN
;
Qianqian XU
;
Shaozhen HUANG
;
Jiudong MA
;
Kun TANG
Author Information
1. 湛江市中心人民医院临床药学室,湛江 524000
- Keywords:
Rituximab;
Cyclosporine;
Focal segmental glomerulosclerosis;
Pharmaceutical care
- From:
Herald of Medicine
2024;43(8):1326-1331
- CountryChina
- Language:Chinese
-
Abstract:
Objective This article reported the treatment process and pharmaceutical monitoring points of a 73 year old patient with latent tuberculosis and positive hepatitis B core antibody,whose focal segmental glomerulosclerosis(FSGS)was trea-ted with cyclosporine and rituximab instead of glucocorticoids because of gastrointestinal ulcer.Methods Clinical pharmacist participated in the treatment process of immunosuppressive therapy,infection prevention,and complications management of ne-phrotic syndrome,and then conducted pharmaceutical monitoring.Results The patient's nephrotic syndrome was relieved,and the urine protein decreased from around 8 g to below 1 g,indicating good disease control.Conclusion The combination of rituximab and cyclosporine could achieve in partial or nearly complete relief of nephrotic syndrome.For patients with latent tuber-culosis and hepatitis B core antibody positive,attention should be paid to the prevention of infection when using immunosuppres-sants such as monoclonal antibody.As patients with nephrotic syndrome were treated with multiple medications,drug interactions and concentrations monitoring should be focused on when using cyclosporine,as well as regular follow-up of patients and guarding against adverse reactions including renal dysfunction and infection.The participation of clinical pharmacists in the clinical therapy was of great significance,which ensured the effectiveness of disease treatment and medication safety.
